You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
博拓生物(688767.SH):預計2021年度淨利潤將增加4億元-4.5億元
格隆匯 01-14 18:14

格隆匯1月14日丨博拓生物(688767.SH)公佈2021年年度業績預增公吿,經財務部門初步測算,預計2021年年度實現歸屬於母公司所有者的淨利潤與上年同期(法定披露數據)相比,將增加4億元到4.5億元,同比增加(或減少)XX%左右(或XX%到XX%)。

歸屬於母公司所有者的扣除非經常性損益的淨利潤與上年同期(法定披露數據)相比,將增加XX萬元(或XX萬元到XX萬元),同比增加XX%左右(或XX%到XX%)。

業績變化的主要原因:

報吿期內,新冠疫情在全球仍在持續反覆,公司繼續全力支持全球疫情防控事業,2021年上半年,公司的新型冠狀病毒抗原檢測試劑盒主要在歐洲地區取得了巨大的銷售業績,下半年,公司研發的新型冠狀病毒抗原家庭自測試劑盒獲得了歐盟CE、澳大利亞TGA註冊,同時受德爾塔和奧密克戎等變種新冠病毒影響,歐洲、澳大利亞等國家和地區新冠感染病例數持續保持較大增長,對新冠抗原檢測試劑需求大幅增加,直接導致了公司海外新冠檢測試劑收入大幅增長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account